Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 21

1503TiP - A phase II study of cemiplimab plus BNT116 versus cemiplimab alone in first-line treatment of patients with advanced non-small cell lung cancer with PD-L1 expression ≥50%

Date

21 Oct 2023

Session

Poster session 21

Topics

Immunotherapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Mark Awad

Citation

Annals of Oncology (2023) 34 (suppl_2): S755-S851. 10.1016/S0923-7534(23)01943-9

Authors

M.M. Awad1, Y. Hao2, S. Li2, M. Kaul3, F. Seebach4, P. Goncalves5, P. Brück6, P. Rietschel7

Author affiliations

  • 1 Department Of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 02215 - Boston/US
  • 2 Biostatistics, Regeneron Pharmaceuticals, Inc., 10591 - Tarrytown/US
  • 3 Global Patient Safety, Regeneron Pharmaceuticals, Inc., 10591 - Tarrytown/US
  • 4 Regulatory Affairs, Regeneron Pharmaceuticals, Inc., 10591 - Tarrytown/US
  • 5 Clinical Sciences, Oncology, Regeneron Pharmaceuticals, Inc., 10591 - Tarrytown/US
  • 6 Clinical Development, BioNTech SE, 55131 - Mainz/DE
  • 7 Clinical Sciences Oncology Department, Regeneron Pharmaceuticals, Inc., 10591 - Tarrytown/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1503TiP

Background

Cemiplimab is an anti–programmed cell death-1 (PD-1) antibody approved as first-line monotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with ≥50% PD-ligand 1 (PD-L1) tumour cell expression. A high unmet medical need remains for patients with no or limited response to anti–PD-1/PD-L1 therapy. As prognosis is poor for these patients, there is growing interest in combining anti–PD-1 compounds with therapeutic cancer vaccines. BNT116 is an investigational mRNA-based therapeutic cancer vaccine consisting of a fixed set of 6 liposomally formulated RNAs, each encoding a different tumour-associated antigen frequently expressed in NSCLC.

Trial design

This is a randomised, multicentre, open-label phase 2 study of cemiplimab plus BNT116 versus cemiplimab alone in treatment-naive patients with stage IIIB, IIIC, or IV squamous or non-squamous NSCLC, who are ineligible for surgical resection or definitive chemoradiation. Patients must have PD-L1 expression on ≥50% of tumour cells (determined by analysis of resected tumour samples) and no actionable EGFR, ALK, or ROS1 aberrations. Patients in arm A will receive cemiplimab beginning Cycle 1 Day 1 (C1D1). Patients in arm B will receive cemiplimab beginning C1D1 and BNT116. The primary endpoint is objective response rate per blinded independent review committee of cemiplimab plus BNT116 versus cemiplimab alone. Secondary endpoints will assess other antitumour activities of cemiplimab plus BNT116 versus cemiplimab alone, as measured by objective response rate per investigator assessment, duration of response, progression-free survival, and overall survival, as well as safety and tolerability. Enrollment of up to 100 patients is planned. Enrolment is ongoing.

Clinical trial identification

NCT05557591.

Editorial acknowledgement

Medical writing support was provided by Talya Underwood of Prime, Knutsford, UK, funded by Regeneron Pharmaceuticals, Inc.

Legal entity responsible for the study

Regeneron Pharmaceuticals, Inc.

Funding

Regeneron Pharmaceuticals, Inc., and BioNTech SE.

Disclosure

M.M. Awad: Financial Interests, Personal, Advisory Role: Merck, Bristol Myers Squibb, Genentech, AstraZeneca, Nektar, Maverick, Blueprint Medicines, Syndax, AbbVie, Gritstone, ArcherDX, Mirati, NextCure, EMD Serono; Financial Interests, Personal, Research Funding: Bristol Myers Squibb, Lilly, Genentech, AstraZeneca. Y. Hao, S. Li, M. Kaul, F. Seebach, P. Goncalves, P. Rietschel: Financial Interests, Personal, Full or part-time Employment: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc. P. Brück: Financial Interests, Personal, Full or part-time Employment: BioNTech SE; Financial Interests, Personal, Stocks/Shares: BioNTech SE.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.